Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.76 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.66 |
| ▸ | CDK4 | P11802 | 1/20 | 0.60 |
| ▸ | CCND1 | P24385 | 1/20 | 0.60 |
| ▸ | NAMPT | P43490 | 1/20 | 0.59 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5598218 | 0.92 | HIF1A (0.85) | HIF1ASMN1; SMN2TRPV1NAMPTP2RX7 | |
| SCHEMBL14082499 | 0.87 | HIF1A (0.76) | HIF1ASMN1; SMN2TRPV1CDK4CCND1 | |
| SCHEMBL11258591 | 0.87 | HIF1A (0.76) | HIF1ASMN1; SMN2TRPV1CDK4CCND1 | |
| SCHEMBL3639491 | 0.86 | HIF1A (0.75) | HIF1ASMN1; SMN2TRPV1NAMPTMAPT | |
| SCHEMBL1568227 | 0.84 | HIF1A (0.72) | HIF1ASMN1; SMN2TRPV1NAMPTP2RX7 | |
| SCHEMBL14082119 | 0.83 | HIF1A (0.70) | HIF1ASMN1; SMN2TRPV1NAMPTP2RX7 | |
| SCHEMBL14082174 | 0.83 | P2RX7 (0.73) | HIF1ASMN1; SMN2TRPV1NAMPTP2RX7 | |
| SCHEMBL28601294 | 0.83 | HIF1A (0.70) | HIF1ASMN1; SMN2TRPV1P2RX7NPC1 | |
| SCHEMBL28598668 | 0.82 | HIF1A (1.00) | HIF1AP2RX7 | |
| SCHEMBL13073425 | 0.81 | HDAC2 (0.76) | HIF1ASMN1; SMN2NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110407824-B | Aryl formamide compound and preparation method, pharmaceutical composition and application thereof | 安徽医科大学 | 2021-07-02 | — | — | CN | disclosed |
| US-20090042855-A1 | BENZAMIDE mGluR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | DEPARTMENT OF VETERANS AFFAIRS | 2009-02-12 | — | — | US | disclosed |
| WO-2008151184-A1 | BENZAMIDE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042855-A1 | BENZAMIDE mGluR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | GRM5, GRIK5, GRM3 | HIF1A 3942/4885SMN1; SMN2 2385/4885TRPV1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.